Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD
Contrary to concerns regarding malignancy, venous thromboembolism, and major adverse cardiac events, the use of Janus kinase (JAK) inhibitors is not associated with a significant increase in the overall risk for these conditions in patients with atopic dermatitis (AD), according to a systematic review and meta-analysis, published in the Journal of the European Academy of Dermatology & Venereology. Recently, […]